enEvolv Revolutionizes Biomanufacturing with MAGE Technology: Ultra-High-Throughput Screening of Billions of Engineered Cells Accelerates Discovery and Production

In recent years, significant progress has been made in the field of industrial microbiology, driven by the rapid development of synthetic biology, gene-editing technologies such as CRISPR/Cas9, and other high-throughput automated screening techniques. The application of these technologies has not only accelerated the process of strain selection and engineering but also enhanced the production performance of industrial microorganisms, enabling them to play an increasingly vital role in biomanufacturing, pharmaceuticals, food, chemical engineering, and other sectors.

Despite the rapid industry development and huge market potential, this field also faces a series of challenges, including the limitations of gene editing technology, the complexity of metabolic pathway design, the efficiency bottleneck of gene expression regulation, high-throughput screening technologies, and the difficulty in activating microbial "dark matter of life," all of which are key points that need to be broken through urgently.

First, the limitations of gene editing technologies are particularly evident in certain industrial microorganisms; for instance, the complex cell wall structure of *Corynebacterium glutamicum* significantly hinders the efficiency of exogenous DNA transformation and genetic modification. Second, the complexity involved in designing and reconstructing metabolic pathways requires researchers to rely not only on empirical experience but also, more urgently, on high-precision digital cell models to provide accurate design blueprints. Furthermore, despite continuous advancements in gene expression regulation technologies, existing methods still lack sufficient efficiency and throughput for the simultaneous regulation of multiple genes. The inadequacy of high-throughput screening technologies limits the ability to rapidly identify superior strains, while activating the microbial “dark matter of life”—namely, the vast number of genes that remain silent during the synthesis of natural products—is key to overcoming bottlenecks in the discovery of novel natural products.

In the face of these challenges, synthetic biologists have been exploring innovative solutions. Among them, enEvolv has brought revolutionary innovation to this field with its breakthrough MAGE (Multiplex Automated Genome Engineering) technology.

MAGE technology enables multiplex genome modifications by introducing synthetic single-stranded DNA during chromosomal replication through high-throughput screening and genome engineering techniques, thereby significantly enhancing the efficiency and throughput of gene editing. This technology not only overcomes the limitations of traditional gene editing methods but also holds promise for activating microbial “dark matter” of life, facilitating the translation from laboratory research to industrial applications and ushering in unprecedented development opportunities for the biotechnology sector.

enEvolv, founded in 2011, is a U.S.-based synthetic biology company that leverages its proprietary MAGE technology to develop and license microbes for the production of chemicals, enzymes, and small molecules across multiple industries, including specialty chemicals, food, energy, personal care, and pharmaceuticals.

Among the founding team of enEvolv, the most prominent figure is Professor George Church. A Professor of Genetics at Harvard Medical School, Professor Church is also a co-founder of enEvolv. His research in synthetic biology and genomics has had a profound impact; he not only participated in the Human Genome Project but also pioneered multiple gene sequencing and editing technologies, including CRISPR-Cas9.

Building on research into MAGE technology, Professor Church’s laboratory at Harvard University incubated enEvolv. enEvolv holds exclusive licenses to multiple foundational patents from the Harvard lab, which have been successfully applied across various commercial sectors.

In addition to George Church, enEvolv’s CEO Colin South and COO Jay Konieczka have also played significant roles in shaping the company’s technological and product development, jointly driving enEvolv’s innovation and growth in the field of synthetic biology.

enEvolv’s MAGE technology achieves multi-site genomic modifications by introducing synthetic single-stranded DNA during chromosomal replication. The advantage of this technology lies in its ability to simultaneously edit multiple gene loci, significantly enhancing the efficiency of genome engineering and generating substantial genetic variation within a short timeframe, thereby accelerating the evolutionary process.

Notably, MAGE technology also offers an innovative solution to the challenge of activating microbial “dark matter of life.” This term refers to the vast number of biosynthetic genes that remain “silent” during the natural product synthesis process in microbes, with their products largely underutilized. Effectively activating these silent genes is key to overcoming the bottleneck in the discovery of new natural products.

enEvolv’s technology platform is centered on biosensors, enabling the screening of billions of individual engineered cells within a single day and the detection of target molecules with exceptional sensitivity and specificity. This ultra-high-throughput screening technology allows enEvolv to screen and identify microbial strains with production potential across an extensive range, thereby activating silent genes and facilitating the discovery and production of novel compounds.

Furthermore, enEvolv’s MAGE technology provides a novel platform for microbial strain engineering through automated genome editing. This technology not only enhances the efficiency and throughput of gene editing but also accelerates the process of biological evolution, facilitating the discovery and development of new compounds with pharmaceutical potential. This holds significant importance for the development of novel antibiotics and for increasing the yield of natural products.

In this way, enEvolv Inc. is able to promote the application of synthetic biology in fields such as drug development, bringing unprecedented opportunities for growth to the biotechnology sector.

In summary, MAGE technology provides a powerful tool in the field of synthetic biology for the genetic improvement of microorganisms and the optimization of metabolic pathways, leveraging its efficient, multi-site genome editing capabilities, thereby advancing the application of biotechnology across multiple industries.

However, MAGE technology also faces several challenges in practical applications. First, this technology is currently primarily implemented in model microorganisms, and its application to non-model organisms may require further development and adaptation. Second, the successful implementation of in vivo continuous evolution technologies largely depends on efficient screening methods; without effective screening, the evolutionary process may be difficult to achieve. Furthermore, MAGE technology may require strict control over mutation rates during implementation to avoid generating excessive harmful variants. Finally, some in vivo continuous evolution techniques may necessitate complex experimental equipment or conditions, which could limit their application in certain research or production environments.

Despite these challenges, MAGE technology has demonstrated significant promise due to its application potential in the fields of synthetic biology and microbial engineering. Through continuous research and technological innovation, MAGE is poised to play an increasingly important role in the future of biotechnology.

On March 19, 2020, synthetic biology company Zymergen announced the acquisition of enEvolv, a move that accelerated Zymergen’s ability to bring revolutionary new products to market and further advanced the speed and scale of bio-manufacturing.

Through this acquisition, Zymergen aims to establish a joint biomanufacturing platform with enEvolv to accelerate research and development in the field of biomanufacturing. Zymergen will leverage enEvolv’s ultra-high-throughput technology to screen individual cells from millions, identifying those with the genes and rare traits required for biomanufacturing applications. According to enEvolv, this platform can accomplish in one month what would take 30 high-speed machines 2,000 years to complete today.

In response, George Church, co-founder of enEvolv and Professor of Genetics at Harvard Medical School, stated that the Zymergen team has cracked the code on how to bring powerful new discoveries to market in a cost-effective and scalable manner. By combining the talents and capabilities of enEvolv and Zymergen, the transformation of product and materials manufacturing will be accelerated.

Joshua Hoffman, CEO of Zymergen, stated that the acquisition of enEvolv will accelerate Zymergen’s ability to bring revolutionary new products to market and further advance the speed and scale of biomanufacturing. By combining enEvolv’s high-throughput screening technology with Zymergen’s strengths in engineering, automation, and machine learning, Zymergen’s capacity to discover, design, and commercialize biomanufactured materials across various industries will be significantly enhanced.

Furthermore, the addition of enEvolv provides Zymergen with an additional office location in Boston, facilitating better collaboration with partners on the East Coast and attracting talent from New England’s rich scientific, technological, and academic communities.

It is reported that prior to its acquisition by Zymergen, enEvolv had 607 employees, representing a 40.2% year-over-year increase in headcount from 2020 to the end of 2021.

Looking ahead, enEvolv will focus on technological innovation, product development, expansion of commercial applications, and the integration of talent and resources to achieve its long-term development goals in the field of synthetic biology. Meanwhile, the company will strengthen collaboration with the scientific and industrial communities to foster technological innovation and talent development.